Altrenogest veterinary grade API is a synthetic C21 progestogen supplied as a white to off-white crystalline powder. The compound, 17α-allyl-17β-hydroxyestra-4,9,11-trien-3-one, has CAS registry number 850-52-2, molecular formula C21H26O2, and relative molecular mass 310.43 g/mol. The active substance belongs to the triene progestogen class and is used as the starting material for oral tablets, capsules, granules, powders, feed premix, and injectable solutions or suspensions. Compendial release testing generally includes an HPLC assay against a certified reference standard, with acceptance limits of 98.0% to 102.0% on the dried basis, related substances by area normalization, residual solvents according to ICH Q3C, water content by Karl Fischer titration, and residue on ignition. The API is practically insoluble in water; this solubility characteristic defines many downstream formulation constraints for aqueous injection and feed delivery systems. It is manufactured in standard unmicronized, micronized, and low-endotoxin grades, depending on the intended route of administration. The material is not a sterile product; terminal sterilization or aseptic processing is the responsibility of the finished dosage manufacturer. Supplier grade designations are not internationally standardized and should be confirmed against the relevant drug master file or veterinary master file.

What Distinguishes Altrenogest from Native Progesterone in Oral Equine Suppression?

Native progesterone is rapidly metabolised by the liver after oral administration, and the oral route is generally not used for equine estrus suppression because first-pass conversion to reduced metabolites lowers systemic exposure. Altrenogest is orally active because the 17α-allyl substituent and the 4,9,11-trien-3-one conjugation slow hepatic biotransformation relative to progesterone. In cyclic mares, the labeled oral dose is 0.044 mg/kg body weight once daily for 15 consecutive days. In sexually mature gilts and sows, oral administration of 15 mg per animal per day for 18 days is used for synchronization of estrus after withdrawal. Suppression is not immediate; follicular activity is depressed over several days of continuous dosing. Published product labels specify that treated mares should be handled as potentially fertile during the first 3 days of therapy when treatment is initiated in mid-diestrus. The API should not be considered interchangeable with native progesterone or with prostaglandin F2α products; altrenogest acts by progestogenic feedback inhibition of gonadotropin release, whereas prostaglandin F2α is luteolytic and requires the presence of a mature corpus luteum.

For tablet and capsule manufacture, the crystalline API is typically dry-blended with microcrystalline cellulose and lactose monohydrate in a high-shear granulator. Because the compound is non-hygroscopic but poorly water-soluble, wet granulation using a binder solution of hypromellose in purified water is preferred over direct compression when the API content exceeds 10% w/w of the tablet mass. The wet mass is dried in a fluid-bed dryer at an inlet air temperature not exceeding 60 °C, with final loss-on-drying controlled between 1.0% and 2.0% w/w. Milling through a 0.8 mm screen followed by lubrication with magnesium stearate for 5 minutes provides acceptable flow. Tablet hardness in the range 6 to 8 kp and disintegration time below 15 minutes in 0.1 M hydrochloric acid are common in-process targets. Finished product uniformity is assessed by content uniformity testing under USP <905>; dissolution testing, where specified, may use a paddle apparatus at 50 rpm with a surfactant-containing medium because of the poor aqueous solubility. Batch records should require protection from light and exclusion of strong oxidising agents; the triene system in altrenogest can undergo oxidative discoloration if exposed to peroxides or prolonged ultraviolet light.

Micronization, Sterility, and Oil Vehicle Requirements for Injectable Preparations

Injectable altrenogest products are formulated either as sterile oil solutions or as aqueous suspensions. For solutions, the API is dissolved in a vegetable-oil vehicle such as sesame oil or fractionated coconut oil, often with benzyl alcohol at 1.0% to 2.0% v/v as a preservative and analgesic. Filtration through a 0.22 µm PVDF membrane under aseptic conditions is used because terminal autoclaving may increase related substances above the specification limit. For suspension products, the API is micronized in a jet mill using nitrogen as the grinding gas, with a particle size target of D90 ≤ 15 µm and D50 ≤ 5 µm to prevent needle clogging and to maintain dose uniformity. Particle size is measured by laser diffraction under ISO 13320:2020. Sterility of the finished injection is tested according to USP <71>; bacterial endotoxin limits are set according to USP <85>; particulate matter is controlled according to USP <788> for subvisible particles. The API itself is non-sterile and should be handled in an ISO Class 8 cleanroom at minimum before final aseptic filtration. The oil vehicle should be purged with nitrogen during heating and cooling; residual oxygen above 2% v/v in the headspace can promote oxidative degradation during long-term storage.

Feed-grade altrenogest premix is commonly supplied as a 0.22% w/w concentrate on a lactose or corn-cob carrier. Preparation in a double-ribbon blender involves geometric dilution of the API into the carrier in three equal-volume steps, followed by 20 minutes mixing at 25 rpm. Homogeneity is verified by taking 10 sampling points with a grain thief according to ISO 6497:2002; the relative standard deviation of altrenogest content by HPLC should be below 5.0% for the premix. The premix is subsequently diluted to provide 15 mg altrenogest per sow or gilt per day in a top-dress feed portion, not in the total daily ration, to limit underdose risk from sorting. Overmixing beyond 45 minutes may induce segregation because the API crystals have higher density than the corn-cob carrier. Heat exposure above 40 °C during storage or pelleting should be validated by assay and related substances; steam conditioning and pelleting may degrade altrenogest if the meal temperature exceeds 70 °C for more than 2 minutes. These limits are process-specific and should be confirmed by recovery studies on the actual mixer geometry and carrier particle size distribution.

When Residual Solvent Levels Approach ICH Q3C Option 1 Limits for a Parenteral Grade

Altrenogest prepared by allylation and subsequent crystallization may retain methanol, dichloromethane, or ethyl acetate, depending on the route of synthesis. Residual solvent testing is performed by headspace gas chromatography using flame ionization detection, with a DB-624 column or equivalent; the method is validated according to USP <467>. For a parenteral-grade API, Class 2 solvents must be controlled below the Option 1 limits stated in ICH Q3C: methanol 3000 ppm, dichloromethane 600 ppm, and toluene 890 ppm. Class 3 solvents such as ethyl acetate and acetone are controlled below 5000 ppm as total residual solvent or per supplier specification. Hot air drying at 60 °C for 4 to 6 hours reduces methanol but may be insufficient for dichloromethane removal from deep crystal lattice sites; in such cases vacuum drying at 10 to 20 kPa for 8 hours is required. Solvent residues above these limits alter the acceptability of the API for parenteral use because residual dichloromethane is a Class 2 solvent with a permitted daily exposure of 6.0 mg/day under ICH Q3C Option 1. Published data for altrenogest-specific desolvation is limited; release limits should be confirmed against site-specific batch data and current pharmacopeial monograph updates.

Degradation chemistry of altrenogest is dominated by oxidation of the 4,9,11-triene chromophore and by acid-catalysed rearrangement of the tertiary allylic alcohol at C17. The API should be stored in a tight, light-resistant container under an inert atmosphere where prolonged warehouse storage exceeds 24 months. Compatibility with excipients should be assessed by binary mixture studies at 40 °C / 75% RH for 4 weeks; alkaline fillers such as dibasic calcium phosphate can promote degradation, while organic peroxides from polyethylene glycols may initiate radical oxidation. A relationship between moisture content above 0.5% w/w and increased hydrolysis cannot be excluded for the 17β-alcohol; Karl Fischer testing at release and after storage is therefore a control point. The product should not be micronized in air if static discharge forms ozone or if residual oxygen in the mill exceeds 2% v/v; nitrogen inerting is standard. Crystalline form should be monitored by X-ray powder diffractometry to ensure batch consistency; published data on altrenogest polymorphic forms is limited.

Compared with native progesterone, altrenogest exhibits oral activity in equids because the 17α-allyl group and the extended conjugation at the 4,9,11 positions reduce hepatic clearance. Native progesterone is endogenous and poorly suited to oral equine suppression; altrenogest is synthetic and is not an endogenous analyte in trace-level veterinary residue methods. It differs from prostaglandin F2α products by mechanism and timing: altrenogest suppresses follicular maturation while prostaglandin F2α induces luteolysis and requires a mature corpus luteum. It differs from medroxyprogesterone acetate in its oral equine indication; published comparative pharmacokinetic data across species is limited, and equivalence should not be assumed. The API should be incorporated into formulations on the basis of the specific dose established for the target species, not by extrapolation from other progestins.

Occupational exposure to altrenogest powder should be controlled to 1.0 µg/m³ as an internal band limit if no national occupational exposure limit is published; this figure is not a regulatory OEL and should be reviewed by a qualified toxicologist. Female workers of childbearing potential should avoid skin contact because the compound is a progestogen and may be absorbed through intact skin. The API is not approved as a single chemical for direct administration; finished veterinary medicines must be registered according to national or regional marketing authorization requirements. Use in animals intended for human consumption is subject to maximum residue limit evaluation; the manufacturer of the API should provide a valid veterinary master file or drug master file to the holder of the finished product.